Tyler Bloomer is a Cardiology physician. OpenAlex indexes 10 publications with 2,406 citations (h-index 3).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1300 W Terrell Ave Ste 500
Fort Worth, TX 761042810
Telephone
817-252-5000Registry record last updated 25 Jun 2019.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20259 payments
- Edwards Lifesciences CorporationProgram year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
77.9%Statin20.6%Rosuvastatin Calcium64%Atorvastatin Calcium31%Crestor2%Pravastatin Sodium2%Part D<11 patientsBeta blocker19.6%Metoprolol Succinate62%Carvedilol25%Metoprolol Tartrate13%Part D≥97 patients+ 12 more classes in this area
Blood & clotting
14.6%Factor Xa inhibitor10.9%Eliquis79%Xarelto21%Part D<11 patientsP2Y12 inhibitor3.7%Clopidogrel100%Part D≥29 patientsMetabolism & gastrointestinal
7.5%SGLT2 inhibitor5.2%Jardiance100%Part D≥25 patientsPotassium supplement1.5%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- CARDIAC GRANULOCYTIC SARCOMA CAUSING INFLOW OBSTRUCTION AND USE OF MAGNETIC RESONANCE IMAGING
Journal of the American College of Cardiology
2018 - Safety of catheter‐directed thrombolysis for massive and submassive pulmonary embolism: Results of a multicenter registry and meta‐analysis
Catheterization and Cardiovascular Interventions
2017 - MYOCARDITIS AND RHABDOMYOLYSIS INCIDENCE WITH IMMUNE CHECKPOINT INHIBITORS
Journal of the American College of Cardiology
2017 - PACING-INDUCED CARDIOMYOPATHY FROM A TRANSCATHETER LEADLESS PACEMAKER FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT
Journal of the American College of Cardiology
2017 - ACCESS SITE AND BLEEDING OUTCOMES WITH ULTRASOUND-ASSISTED CATHETER-DIRECTED THROMBOLYSIS FOR ACUTE PULMONARY EMBOLISM: INTERNAL JUGULAR VERSUS COMMON FEMORAL VEIN
Journal of the American College of Cardiology
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”